MS drug candidate shows positive results for myelin repair in cell culture assay
Bionure Inc. has announced its drug candidate, BN201, was shown to promote myelination — the cellular process of repairing the protective sheath surrounding nerves that is damaged in people with multiple sclerosis (MS). The pre-clinical study was conducted in a novel cell-culture assay developed by the Myelin Repair Foundation (MRF) and assessed at the Foundation’s Translational Medicine Center under a previously announced collaborative agreement..... Read More - http://www.ms-uk.org/myelin
MS drug candidate shows positive results for myelin repair.
MS drug candidate shows positive results for myelin repair.
MS-UK - http://www.ms-uk.org/
Re: MS drug candidate shows positive results for myelin repair.
2019 Feb 27
Center for Neuroimmunology, Institut d'Investigacions Biomediques August Pi Sunyer, Barcelona, Spain
Myelin Repair Foundation, Saratoga
Stanford University, Palo Alto
Axonal and Myelin Neuroprotection by the Peptoid BN201 in Brain Inflammation.
https://www.ncbi.nlm.nih.gov/pubmed/30815844
Abstract
The development of neuroprotective therapies is a sought-after goal. By screening combinatorial chemical libraries using in vitro assays, we identified the small molecule BN201 that promotes the survival of cultured neural cells when subjected to oxidative stress or when deprived of trophic factors. Moreover, BN201 promotes neuronal differentiation, the differentiation of precursor cells to mature oligodendrocytes in vitro, and the myelination of new axons. BN201 modulates several kinases participating in the insulin growth factor 1 pathway including serum-glucocorticoid kinase and midkine, inducing the phosphorylation of NDRG1 and the translocation of the transcription factor Foxo3 to the cytoplasm. In vivo, BN201 prevents axonal and neuronal loss, and it promotes remyelination in models of multiple sclerosis, chemically induced demyelination, and glaucoma. In summary, we provide a new promising strategy to promote neuroaxonal survival and remyelination, potentially preventing disability in brain diseases.
Center for Neuroimmunology, Institut d'Investigacions Biomediques August Pi Sunyer, Barcelona, Spain
Myelin Repair Foundation, Saratoga
Stanford University, Palo Alto
Axonal and Myelin Neuroprotection by the Peptoid BN201 in Brain Inflammation.
https://www.ncbi.nlm.nih.gov/pubmed/30815844
Abstract
The development of neuroprotective therapies is a sought-after goal. By screening combinatorial chemical libraries using in vitro assays, we identified the small molecule BN201 that promotes the survival of cultured neural cells when subjected to oxidative stress or when deprived of trophic factors. Moreover, BN201 promotes neuronal differentiation, the differentiation of precursor cells to mature oligodendrocytes in vitro, and the myelination of new axons. BN201 modulates several kinases participating in the insulin growth factor 1 pathway including serum-glucocorticoid kinase and midkine, inducing the phosphorylation of NDRG1 and the translocation of the transcription factor Foxo3 to the cytoplasm. In vivo, BN201 prevents axonal and neuronal loss, and it promotes remyelination in models of multiple sclerosis, chemically induced demyelination, and glaucoma. In summary, we provide a new promising strategy to promote neuroaxonal survival and remyelination, potentially preventing disability in brain diseases.
https://www.eboro.cz